Article
Biosimilar Litigation Review: BPCIA Federal Circuit Appeals Pending & Recently Decided
Authors
-
- Name
- Person title
- Associate
Part three of a four-part series on 2019 legal developments related to the biosimilar sector is now available. Written by Fish principal Jenny Shmuel and associates Philip Chen and Felix Eyzaguirre, this article focuses on Biosimilars Price Competition and Innovation Act (BPCIA) Federal Circuit appeals that are pending and those that were recently decided.
Read the “Biosimilar Litigation Review: BPCIA Federal Circuit Appeals Pending & Recently Decided” full article.
The opinions expressed are those of the authors on the date noted above and do not necessarily reflect the views of Fish & Richardson P.C., any other of its lawyers, its clients, or any of its or their respective affiliates. This post is for general information purposes only and is not intended to be and should not be taken as legal advice. No attorney-client relationship is formed.